291 related articles for article (PubMed ID: 11122141)
1. Additional chromosomal abnormalities in patients with acute promyelocytic leukaemia (APL) do not confer poor prognosis: results of APL 93 trial.
De Botton S; Chevret S; Sanz M; Dombret H; Thomas X; Guerci A; Fey M; Rayon C; Huguet F; Sotto JJ; Gardin C; Cony Makhoul P; Travade P; Solary E; Fegueux N; Bordessoule D; San Miguel J; Link H; Desablens B; Stamatoullas A; Deconinck E; Geiser K; Hess U; Maloisel F; Castaigne S; Preudhomme C; Chomienne C; Degos L; Fenaux P;
Br J Haematol; 2000 Dec; 111(3):801-6. PubMed ID: 11122141
[TBL] [Abstract][Full Text] [Related]
2. Characteristics and prognosis analysis of additional chromosome abnormalities in newly diagnosed acute promyelocytic leukemia treated with arsenic trioxide as the front-line therapy.
Lou Y; Suo S; Tong H; Ye X; Wang Y; Chen Z; Qian W; Meng H; Mai W; Huang J; Tong Y; Jin J
Leuk Res; 2013 Nov; 37(11):1451-6. PubMed ID: 23958062
[TBL] [Abstract][Full Text] [Related]
3. Additional chromosome abnormalities in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy.
Cervera J; Montesinos P; Hernández-Rivas JM; Calasanz MJ; Aventín A; Ferro MT; Luño E; Sánchez J; Vellenga E; Rayón C; Milone G; de la Serna J; Rivas C; González JD; Tormo M; Amutio E; González M; Brunet S; Lowenberg B; Sanz MA
Haematologica; 2010 Mar; 95(3):424-31. PubMed ID: 19903674
[TBL] [Abstract][Full Text] [Related]
4. Secondary cytogenetic changes in acute promyelocytic leukemia--prognostic importance in patients treated with chemotherapy alone and association with the intron 3 breakpoint of the PML gene: a Cancer and Leukemia Group B study.
Slack JL; Arthur DC; Lawrence D; Mrózek K; Mayer RJ; Davey FR; Tantravahi R; Pettenati MJ; Bigner S; Carroll AJ; Rao KW; Schiffer CA; Bloomfield CD
J Clin Oncol; 1997 May; 15(5):1786-95. PubMed ID: 9164186
[TBL] [Abstract][Full Text] [Related]
5. Trisomy 21 and other chromosomal abnormalities in acute promyelocytic leukemia.
Wan TS; Ma SK; Au WY; Liu HS; Chan JC; Chan LC
Cancer Genet Cytogenet; 2003 Jan; 140(2):170-3. PubMed ID: 12645658
[TBL] [Abstract][Full Text] [Related]
6. [Effect of all-trans retinoic acid on the newly diagnosed acute promyelocytic leukaemia: our experience].
Rolovitsh Z; Cholovitsh M; Elezovitsh I; Vidovitsh A; Radoshevitsh-Radojkovitsh N; Boshkovitsh D; Novak A; Basara N
Srp Arh Celok Lek; 1995; 123(11-12):279-85. PubMed ID: 16296239
[TBL] [Abstract][Full Text] [Related]
7. All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol.
Tallman MS; Andersen JW; Schiffer CA; Appelbaum FR; Feusner JH; Woods WG; Ogden A; Weinstein H; Shepherd L; Willman C; Bloomfield CD; Rowe JM; Wiernik PH
Blood; 2002 Dec; 100(13):4298-302. PubMed ID: 12393590
[TBL] [Abstract][Full Text] [Related]
8. [Therapeutic results with apl 93 protocol in acute promyelocytic leukemia (34 cases)].
Jeddi R; Hdiji S; Kacem K; Ben Lakhal R; Aissaoui L; Ben Abid H; Belhadj Ali Z; Meddeb B
Tunis Med; 2006 Nov; 84(11):717-20. PubMed ID: 17294898
[TBL] [Abstract][Full Text] [Related]
9. Incidence, clinical features, and outcome of all trans-retinoic acid syndrome in 413 cases of newly diagnosed acute promyelocytic leukemia. The European APL Group.
De Botton S; Dombret H; Sanz M; Miguel JS; Caillot D; Zittoun R; Gardembas M; Stamatoulas A; Condé E; Guerci A; Gardin C; Geiser K; Makhoul DC; Reman O; de la Serna J; Lefrere F; Chomienne C; Chastang C; Degos L; Fenaux P
Blood; 1998 Oct; 92(8):2712-8. PubMed ID: 9763554
[TBL] [Abstract][Full Text] [Related]
10. t(15;17) hypergranular acute promyelocytic leukemia (M3) developing into a t(3;6) M3 without t(15;17) at relapse.
Desangles F; Vilain E; Arborio M; De Revel T; Flandrin G
Leuk Lymphoma; 1995 Sep; 19(1-2):185-8. PubMed ID: 8574167
[TBL] [Abstract][Full Text] [Related]
11. Cytogenetic studies in acute promyelocytic leukemia: a survey of secondary chromosomal abnormalities.
Berger R; Le Coniat M; Derré J; Vecchione D; Jonveaux P
Genes Chromosomes Cancer; 1991 Sep; 3(5):332-7. PubMed ID: 1797083
[TBL] [Abstract][Full Text] [Related]
12. Acute promyelocytic leukemia. New methods in diagnosis and treatment.
Varghese L; Janckila A; Yam LT
J Ky Med Assoc; 1999 Feb; 97(2):61-5. PubMed ID: 10073058
[TBL] [Abstract][Full Text] [Related]
13. All-trans retinoic acid (ATRA) in the treatment of acute promyelocytic leukemia (APL).
Chim CS; Kwong YL; Liang R; Chu YC; Chan CH; Chan LC; Wong KF; Chan TK
Hematol Oncol; 1996 Sep; 14(3):147-54. PubMed ID: 9119359
[TBL] [Abstract][Full Text] [Related]
14. Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: result of the Randomized MRC Trial.
Burnett AK; Grimwade D; Solomon E; Wheatley K; Goldstone AH
Blood; 1999 Jun; 93(12):4131-43. PubMed ID: 10361110
[TBL] [Abstract][Full Text] [Related]
15. A novel clonal t(1;4)(p36.1;q31) translocation in acute promyelocytic leukaemia.
Zhang X; Pan J
J Clin Pathol; 2015 May; 68(5):391-3. PubMed ID: 25759405
[TBL] [Abstract][Full Text] [Related]
16. Translocation (15;17) and trisomy 21 in the microgranular variant of acute promyelocytic leukemia.
Spell DW; Velagaleti GV; Jones DV; Velasquez WS
Cancer Genet Cytogenet; 2002 Jan; 132(1):74-6. PubMed ID: 11801315
[TBL] [Abstract][Full Text] [Related]
17. Treatment of newly diagnosed acute promyelocytic leukemia (APL) by all transretinoic acid (ATRA) combined with chemotherapy: The European experience. European APL Group.
Fenaux P; Chastang C; Chomienne C; Castaigne S; Sanz M; Link H; Löwenberg B; Fey M; Archim-Baud E; Degos L
Leuk Lymphoma; 1995 Feb; 16(5-6):431-7. PubMed ID: 7787753
[TBL] [Abstract][Full Text] [Related]
18. Prospective study of a therapeutic regimen with all-trans retinoic acid and anthracyclines in combination of cytarabine in children with acute promyelocytic leukaemia: the Japanese childhood acute myeloid leukaemia cooperative study.
Imaizumi M; Tawa A; Hanada R; Tsuchida M; Tabuchi K; Kigasawa H; Kobayashi R; Morimoto A; Nakayama H; Hamamoto K; Kudo K; Yabe H; Horibe K; Tsuchiya S; Tsukimoto I
Br J Haematol; 2011 Jan; 152(1):89-98. PubMed ID: 20735397
[TBL] [Abstract][Full Text] [Related]
19. Additional cytogenetic changes do not influence the outcome of patients with newly diagnosed acute promyelocytic leukemia treated with an ATRA plus anthracyclin based protocol. A report of the Spanish group PETHEMA.
Hernández JM; Martín G; Gutiérrez NC; Cervera J; Ferro MT; Calasanz MJ; Martínez-Climent JA; Luño E; Tormo M; Rayón C; Díaz-Mediavilla J; González M; González-San Miguel JD; Pérez-Equiza K; Rivas C; Esteve J; Alvarez Mdel C; Odriozola J; Ribera JM; Sanz MA;
Haematologica; 2001 Aug; 86(8):807-13. PubMed ID: 11522536
[TBL] [Abstract][Full Text] [Related]
20. [Effect of additional chromosome abnormalities on the outcome of newly diagnosed acute promyelocytic leukemia treated with red arsenic sulfide and all trans-retinoic acid plus anthracyclin based protocol].
Lu J; Jiang H; Jiang Q; Bao L; Lu XJ; Zhang Y; Lin W; Liu YR; Huang XJ; Jiang B
Zhonghua Yi Xue Za Zhi; 2008 Aug; 88(32):2254-7. PubMed ID: 19087672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
